Calculate NLR from CBC results with context-specific thresholds for sepsis, cardiac, oncology, COVID-19, and critical care. Includes PLR, LMR, and SII.
The neutrophil-to-lymphocyte ratio (NLR) is a simple, inexpensive biomarker of systemic inflammation derived from the routine complete blood count (CBC). Calculated by dividing the absolute neutrophil count by the absolute lymphocyte count, NLR reflects the balance between innate immune activation (neutrophils) and adaptive immune regulation (lymphocytes).
Over the past decade, NLR has emerged as a powerful prognostic marker across numerous clinical domains. In oncology, elevated NLR predicts worse overall survival in colorectal, lung, breast, hepatocellular, and pancreatic cancers. In cardiology, NLR >5 independently predicts major adverse cardiac events after acute coronary syndrome. In infectious disease, NLR ≥6 has approximately 80% sensitivity for bacteremia. During the COVID-19 pandemic, NLR ≥3.13 was demonstrated to predict progression to severe disease.
This calculator computes NLR from either absolute counts or WBC differentials, applies context-specific clinical cutoffs, provides population percentile estimates, and optionally calculates related inflammatory ratios including the platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII).
NLR provides a free, immediately available biomarker of systemic inflammation from the routine CBC. No additional tests or costs are required. It adds prognostic value in sepsis screening, cardiac risk stratification, oncology prognosis, and critical care monitoring when interpreted in the appropriate clinical context. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain.
NLR = Absolute Neutrophil Count ÷ Absolute Lymphocyte Count. If using differentials: ANC = WBC × (Neutrophil% / 100), ALC = WBC × (Lymphocyte% / 100). Related ratios: PLR = Platelets ÷ ALC; LMR = ALC ÷ Monocytes; SII = ANC × Platelets ÷ ALC.
Result: NLR 2.57 — Normal range; PLR 119.0; Population 54th percentile
An NLR of 2.57 falls within the normal range (1.0–3.0) for the general population, sitting at approximately the 54th percentile. The PLR of 119 is also within normal limits (<180). No evidence of significant systemic inflammation from these markers.
In the acute care setting, NLR is increasingly used as a rapid triage tool. A CBC with differential is among the first labs drawn in virtually every emergency department workup. NLR ≥6 helps differentiate bacterial infection from viral illness, NLR ≥10 raises suspicion for sepsis, and NLR ≥20 suggests severe sepsis or septic shock. Unlike CRP (which takes hours to rise) or procalcitonin (which is expensive and requires dedicated testing), NLR is available immediately from the initial CBC. Emergency physicians can use NLR to prioritize patients for empiric antibiotics, blood cultures, and ICU disposition.
The link between inflammation and atherosclerosis is well-established, and NLR captures this relationship. In acute coronary syndrome, admission NLR >5 predicts in-hospital mortality, no-reflow phenomenon after PCI, and recurrent events at 1 year. In stable coronary artery disease, NLR predicts future MACE independently of traditional risk factors. The mechanism relates to neutrophil-mediated plaque destabilization and thrombus formation, while lymphopenia reflects impaired vascular healing. Some cardiologists now incorporate NLR into post-ACS risk stratification alongside troponin and ECG findings.
Despite its utility, NLR has important limitations. It is nonspecific — any cause of stress, inflammation, or immune activation alters the ratio. Physical exercise, psychological stress, and even time of day (diurnal cortisol variation) affect NLR. Medications, particularly corticosteroids, can render NLR uninterpretable. NLR does not distinguish between different types of infection, inflammation, or malignancy. Optimal cutoff values vary by population, clinical context, and study methodology. NLR should always be interpreted alongside the complete clinical picture, not in isolation.
In healthy adults, NLR typically ranges from 1.0 to 3.0, with a median around 1.65–2.15 depending on the population studied. Values below 1.0 may indicate relative neutropenia or lymphocytosis (seen in viral infections, some medications, or autoimmune conditions). Values above 3.0 suggest some degree of systemic inflammation. The "normal" range shifts with age and sex — older adults and males tend to have slightly higher NLR.
Yes, NLR is one of the most studied inflammatory biomarkers in oncology. Meta-analyses involving hundreds of thousands of patients have consistently shown that pre-treatment NLR ≥4 is associated with worse overall survival and progression-free survival across solid tumors including colorectal, lung, breast, gastric, hepatocellular, pancreatic, and renal cell carcinomas. NLR reflects the tumor microenvironment: neutrophilia promotes tumor growth while lymphopenia reflects impaired antitumor immunity. Some oncologists use NLR trends to monitor treatment response.
NLR, CRP, and procalcitonin measure different aspects of the inflammatory response. NLR reflects cellular immune balance and is available immediately from any CBC. CRP is a more specific acute-phase protein but takes hours to rise. Procalcitonin is more specific for bacterial infection but is costlier. Studies suggest NLR has comparable diagnostic accuracy to procalcitonin for bacteremia (NLR ≥6: sensitivity ~80%, specificity ~70%). The key advantage of NLR is that it costs nothing extra if a CBC is already ordered.
SII = Neutrophils × Platelets ÷ Lymphocytes. It integrates three immune/inflammatory cell types into a single index. Elevated SII (>900) has been shown to predict worse outcomes in cancer, cardiovascular disease, and critical illness. By incorporating platelets (which reflect both inflammation and thrombotic risk), SII may capture more systemic information than NLR alone. SII is especially studied in hepatocellular carcinoma and colorectal cancer prognosis.
Yes, many medications significantly alter NLR. Corticosteroids cause neutrophilia and lymphopenia, dramatically increasing NLR — even a single dose can double NLR within hours. Chemotherapy can cause neutropenia, lowering NLR. Beta-blockers may slightly lower NLR through stress hormone modulation. Immunotherapy (checkpoint inhibitors) can cause lymphocytosis. Always consider the medication list when interpreting NLR, especially recent corticosteroid exposure.
During the pandemic, NLR emerged as a rapid triage marker. Multiple studies showed NLR ≥3.13 at admission predicted progression to severe COVID-19 (ICU, mechanical ventilation, death). NLR >6 was strongly associated with cytokine storm. While COVID-specific guidelines have evolved, NLR remains a useful early warning marker in any respiratory infection and is part of several validated COVID-19 severity prediction scores. The advantage is its availability from the routine admission CBC.